Overall, Contreras underscored that combining predictive analytics, AI-driven modeling, and digital monitoring can help ...
MedPage Today on MSN
First At-Home Device Approved for Depression
Brain stim indicated as a monotherapy or adjunctive treatment for major depressive disorde ...
WVNS Bluefield on MSN
New depression treatment could accelerate symptom relief
WEST VIRGINIA (WVNS) – Millions of Americans living with major depressive disorder struggle to find treatment options that ...
Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...
News-Medical.Net on MSN
Short-term nitrous oxide treatment could benefit patients with major depressive disorder
Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit ...
The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults. This approval marks ...
Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar depression. Clinical trials showed significant symptom improvement and potential ...
Laughing gas (nitrous oxide) appears to offer rapid mood improvement for people with severe or treatment-resistant depression ...
Major Depressive Disorder (MDD) is increasingly recognised not solely as an affective disorder but also as one characterised by enduring cognitive impairments. These deficits, affecting domains such ...
As the conversation around mental health disorders like depression becomes increasingly normalized, it can also blur the lines between situational feelings of stress, anxiety, and dejection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback